Genzyme Corp. broke ground on a $150 million expansion project at its Allston Landing manufacturing facility in Boston that will add space for manufacturing support functions and will create 90 jobs. Commercial production at Allston Landing, which began in 1996, was initially intended to produce Cerezyme and has grown to include four additional products: Fabrazyme for Fabry disease, Myozyme for Pompe disease, as well as the filling and packaging for Aldurazyme for MPS I disease and Thyrogen, u...